A deterministic transmission model of tuberculosis in India, calibrated to WHO data for 2015 to 2024, evaluated three doses of VPM1002 ten years apart. Estimated effectiveness was 42.9% against disease outside the lungs and 14.0% against lung disease, with both credible intervals including no effect. Per million people targeted, three doses would avert 682 deaths at US$329 per disability-adjusted life-year averted, assuming ten years of protection.
Why it is interesting: The modelled benefit rests on a trial signal whose credible interval still includes no effect.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.